Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000424225 | SCV000520760 | pathogenic | not provided | 2017-01-18 | criteria provided, single submitter | clinical testing | The C52R pathogenic variant in the GLA gene has been reported in at least one patient diagnosed with Fabry disease (Blanch et al., 1996). In addition, variants in the same codon (C52Y, C52W) have been reported in the literature (Parini et al., 2008; Lukas et al., 2013) and classified as a pathogenic or likely pathogenic based on review of the data in the context of the 2015 ACMG Standards and guidelines for the interpretation of sequence variants (Richards et al., 2015). Other missense variants in the same codon (C52G, C52S) have also been reported in the Human Gene Mutation Database in association with Fabry disease (Stenson et al., 2014). The C52R variant results in a non-conservative amino acid substitution at a position that is conserved across species and is involved in a disulfide bond with another residue in the GLA gene. In silico analysis predicts this variant is probably damaging to the protein structure/function. Finally, the C52R pathogenic variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. |
| Eurofins Ntd Llc |
RCV000424225 | SCV000709511 | pathogenic | not provided | 2018-07-10 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV001807250 | SCV002054454 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |